南非生物制剂注册研究:风湿病患者使用生物制剂的结核风险
南非生物制剂注册(SABIO)研究评估了1999年至2017年风湿病患者使用生物制剂后的结核发病率、潜伏结核感染(LTBI)筛查效果及危险因素。生物制剂使用者结核发病率为1240/10万人年,而生物制剂未使用者为0/10万人年;单克隆抗体抑制剂风险高于依那西普和非TNF抑制剂。LTBI筛查是重要预防策略。
要点
- 生物制剂使用者结核发病率显著高于未使用者,以单克隆抗体抑制剂风险最高。
- LTBI筛查阳性者中14例发展为结核,但多数结核病例筛查时为阴性。
- 黑人种族、男性、年轻及居住西开普省为统计危险因素。
核心结论
- 再激活和新发结核是所有生物制剂使用者的显著风险,LTBI筛查是必要预防策略。
研究设计与样本
- 研究收集1999年至2017年6月南非生物制剂注册(SABIO)、风湿科医生和制药公司的结核病例,记录人口学、LTBI筛查治疗、生物制剂和DMARD治疗、结核诊断及结局。
主要发现
- 共收集96例结核病例:类风湿关节炎55例,强直性脊柱炎27例,银屑病关节炎4例,幼年炎性关节炎10例。
- 生物制剂使用者结核发病率为1240/10万人年(n=96),生物制剂未使用者为0/10万人年,发病率差0.0124(p<0.0001)。
- 60/96为肺结核,36/96为肺外结核;再激活结核45/96例。
- 单克隆抗体抑制剂结核发病率为1683/10万人年,依那西普为861/10万人年,非TNF抑制剂为681/10万人年。
- 单克隆抗体抑制剂相比依那西普的发病率比为1.96(p=0.005),相比非TNF抑制剂为2.47(p=0.002);非TNF抑制剂与依那西普无显著差异(p=0.336)。
关键数值与推荐
- LTBI筛查阳性者占12.9%,其中14例发展为结核,多数(77例)筛查时为LTBI阴性。
- 统计危险因素包括黑人种族、男性、年轻年龄和居住西开普省。
- 发生2例耐药结核和6例死亡。
临床怎么用
- 对准备使用生物制剂的风湿病患者应进行LTBI筛查,并优先选择结核风险较低的生物制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the rate of tuberculosis (TB) in biologic users for rheumatic diseases in South Africa, the effectiveness of our latent TB infection (LTBI) programme, risk factors and outcome. METHODS: TB cases were collected from the South African Biologics Registry (SABIO), rheumatologists and pharmaceutical companies. Demographics, LTBI screening and treatment, biological and disease modifying antirheumatic drug (DMARD) therapies, TB diagnosis and outcomes were recorded. RESULTS: 96 TB cases were collected from 1999 to June 2017: rheumatoid arthritis 55, ankylosing spondylitis 27, psoriatic arthritis 4, and juvenile inflammatory arthritis 10. The TB rate was 1240/100 000 person years for biologic users (n=96) versus the biologic naive cohort of 0/100 000 years with an incidence rate difference of 0.0124 (p<0.0001). 60/96 had pulmonary and 36/96 had extra-pulmonary TB. Reactivation TB occurred in 45/96 cases. TB occurred in all biologics licenced in South Africa, the majority in monoclonal inhibitors (1683/100 000 person years) compared with etanercept (861/100 000 person years) and non-tumour necrosis factor (TNF) inhibitors (681/100 000 person years). The incidence rate ratio for monoclonal inhibitors compared with etanercept was 1.96 (p=0.005) and 2.47 (p=0.002) compared with non-TNF inhibitors with no significant difference between non-TNF inhibitors and etanercept (p=0.336). From those (12.9%) who screened LTBI positive, 14 developed TB, while the majority (77) screened LTBI negative. Black race, male sex, younger age and residence in the Western Cape were statistical risk factors. Two drug resistant TB cases and six deaths occurred. CONCLUSION: Reactivation and new onset TB is a significant risk for all biologics users in SA. Screening for LTBI is an imperative preventative strategy.
引用
- Pettipher C, Benitha R. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO). Ann Rheum Dis. 2019. PMID: 31791950. doi:10.1136/annrheumdis-2019-216128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。